Skip to main content
. 2021 Dec 16;7(3):e002010. doi: 10.1136/rmdopen-2021-002010

Table 1.

Demographics and disease characteristics of the study subjects

Parameter (unit) SLE (n=103) HC (n=56)
Age, years; median (IQR) 47 (26) 47 (24)
Female, n (%) 96 (93.2) 36 (64.3)
SLE duration, years; median (IQR) 12 (12) na
SLEDAI, points; median (IQR) 2.0 (4.0) na
SLE history
 Skin involvement, n (%) 88 (85.4) na
 Arthritis, n (%) 86 (83.5) na
 Oral ulcerations, n (%) 38 (36.9) na
 Serositis, n (%) 35 (33.9) na
 CNS involvement, n (%) 31 (30.1) na
 Kidney involvement, n (%) 23 (22.3) na
Clinical parameters
 Systolic blood pressure >140 mm Hg, n (%) 21 (20.4) nd
 Patients on prednisone, n (%) 39 (37.9) na
 Neutrophil count, 109 cells/L; median (IQR) 3.7 (2.2) 2.8 (1.1)
 Platelet count, 109 cells/L; median (IQR) 238 (67.0) 250 (62.3)
 CRP, mg/L; median (IQR) 3.1 (2.6) na
 Urinary protein/creatinine ratio >ULN, n (%) 8 (7.8) na
 Serum creatinine, µmol/L; median (IQR) 67 (20) na
 Hypocomplementaemia (C3 or C4), n (%) 57 (55.9) na
 dsDNA antibody titre, U/mL; median (IQR) 15 (49) na

CNS, central nervous system; CRP, C-reactive protein; dsDNA, double stranded DNA; ESR, erythrocyte sedimentation rate; HC, healthy controls; na, not applicable; nd, not done; SLE, systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; ULN, upper limit of normal.